Mark Patrick Hamilton
The University of Texas MD Anderson Cancer Center, Stanford University, Baylor College of Medicine
Research areas: Medicine · Oncology · CAR-T cell therapy research · T-cell and B-cell Immunology · Cancer Genomics and Diagnostics
0000-0002-3732-8910
About
I am an MD/PhD physician scientist currently working as an Assistant Professor at MD Anderson Cancer Center. I run my own laboratory focused on human correlative genomics in lymphoma. I have worked in the field of human translational research and cancer genomics for more than fifteen years. I recently completed three years of dedicated research under the mentorship of Dr. Ash Alizadeh and Dr. David Miklos where I focus on investigation of CAR-T cells in the clinical setting. This work serves as the basis for my laboratory.
I use clinical and computational methods to study how lymphoma therapies interact with the human immune system. My goal is to understand the mechanisms responsible clinical toxicity and efficacy to design clinical trials that improve safety and long-term remissions in patients with lymphoma. My long-term career goal is to be a leader in the field of lymphoma therapy by using human specimens to understand disease biology and thereby develop new therapies.
Employment
-
The University of Texas MD Anderson Cancer Center Assistant Professor2025 - Present
-
Stanford University Fellow2020 - 2025
Education
- 2009 - 2018
- ? - 2017
Projects & Funding
-
Cell-free DNA analysis of persistent CAR T-cell populations in humans. Leukemia and Lymphoma Society2022 - 2025
Publications (45)
- Clonal hematopoiesis and cytopenias following CAR19 therapy Save
- Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma Save
- Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma Save
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders Save
- CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma Save
- Clonal Hematopoiesis and Cytopenias Following CAR19 Therapy Save
- Expansion and cytotoxicity of mucosal CAR+ T cells in enterocolitis associated with BCMA CAR-T cell therapy Save
- Immune effector cell-associated enterocolitis after ciltacabtagene autoleucel: multicenter characterization of a CAR+ T-cell lymphoproliferative gastrointestinal syndrome Save
- Making the case for ruxolitinib in CAR T-cell enterocolitis Save
- Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL Save
- Large B cell lymphoma microenvironment archetype profiles Save
- CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Save
- A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Save
- Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Save
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Save
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Save
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Save
- Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies Save
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply Save
- Zika virus co-opts microRNA networks to persist in placental niches detected by spatial transcriptomics. Save